Editorial: Gadolinium Use in Patients with Kidney Disease: A Cause for Concern
- 1 May 2007
- journal article
- Published by Wiley in Seminars in Dialysis
- Vol. 20 (3) , 179-185
Abstract
Gadolinium is widely used as a magnetic resonance imaging contrast agent and is considered to have a good overall safety profile. Recently, both renal and extra‐renal toxicities have been reported following exposure to gadolinium in patients with underlying kidney disease. Gadolinium‐related contrast‐induced nephropathy appears to be a risk in patients with advanced kidney disease and especially those with diabetic nephropathy. Even more concerning is the strong association of gadolinium with nephrogenic systemic fibrosis (NSF), a devastating fibrosing disorder of the skin and other systemic organs. Although cause and effect have not been proven for the NSF‐gadolinium link, the impaired renal elimination of gadolinium in patients with kidney disease and the instability of gadolinium‐chelate binding may expose tissues to toxic free Gd3+and promote this fibrosing disorder. Caution should be exercised when utilizing gadolinium as a contrast agent in patients with advanced CKD or ESRD.Keywords
This publication has 28 references indexed in Scilit:
- Nephrogenic Systemic FibrosisInvestigative Radiology, 2007
- Preventing Complications of Radiographic Contrast Media: Is There a Role for Dialysis?Seminars in Dialysis, 2007
- MR contrast agents, the old and the newEuropean Journal of Radiology, 2006
- Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)Current Opinion in Rheumatology, 2006
- A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight DoseInvestigative Radiology, 2006
- Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamideEuropean Radiology, 2006
- Extracorporeal Blood Purification Therapies for Prevention of Radiocontrast-Induced Nephropathy: A Systematic ReviewAmerican Journal of Kidney Diseases, 2006
- Gadolinium‐based contrast agents and nephrotoxicity in patients undergoing coronary artery proceduresCatheterization and Cardiovascular Interventions, 2006
- Nephrotoxicity of high‐dose gadolinium compared with iodinated contrastJournal of Magnetic Resonance Imaging, 1996
- Pharmacokinetics of Gd-DTPA in Patients with Chronic Renal FailureInvestigative Radiology, 1991